Financial Gravity Asset Management, Inc. Biocryst Pharmaceuticals Inc Transaction History

Financial Gravity Asset Management, Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Jun 26, 2024	BUY	$4.89 - $7.65 $29 - $45	6 Added 300.0%	8 $39,000
Q1 2024 May 13, 2024	BUY	$4.89 - $7.65 $73 - $114	15 Added 750.0%	17 $82,000
Q4 2023 Jun 26, 2024	SELL	$4.98 - $6.77 $74 - $101	-15 Reduced 88.24%	2 $10,000
Q3 2023 Nov 15, 2023	SELL	$6.71 - $7.92 $33 - $39	-5 Reduced 71.43%	2 $0
Q2 2023 Aug 08, 2023	SELL	$6.96 - $8.81 $6 - $8	-1 Reduced 12.5%	7 $37,000
Q1 2023 May 12, 2023	SELL	$7.94 - $11.84 $23 - $35	-3 Reduced 27.27%	8 $14,000
Q4 2022 Feb 15, 2023	SELL	$10.5 - $14.2 $157 - $213	-15 Reduced 57.69%	11 $62,000
Q3 2022 Nov 03, 2022	BUY	$10.79 - $14.81 $43 - $59	4 Added 18.18%	26 $21,000
Q2 2022 Aug 05, 2022	SELL	$7.89 - $17.88 $78 - $178	-10 Reduced 31.25%	22 $18,000
Q1 2022 May 13, 2022	BUY	$11.56 - $19.76 $46 - $79	4 Added 14.29%	32 $28,000
Q4 2021 Feb 11, 2022	BUY	$11.18 - $15.46 $290 - $401	26 Added 1300.0%	28 $24,000
Q2 2021 Aug 11, 2021	SELL	$9.5 - $17.24 $28 - $51	-3 Reduced 60.0%	2 $16,000
Q1 2021 May 17, 2021	BUY	$7.37 - $13.61 $36 - $68	5 New	5 $55,000

278

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.45B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Financial Gravity Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Financial Gravity Asset Management, Inc. with notifications on news.